A comparison between the blocking actions of 2-(4-phenylpiperidino) cyclohexanol (AH 5183) and its N-methyl quaternary analogue (AH 5954).
1. The neuromuscular blocking activities of AH 5183 (2-(4-phenylpiperidino) cyclohexanol) and its N-methyl quaternary analogue (AH 5954) were compared in rapidly stimulated nerve-skeletal muscle preparations of the rat, chicken and cat.2. The evidence indicated that in isolated preparations the neuromuscular block produced by both AH 5183 and AH 5954 was primarily pre-junctional in origin. That produced by AH 5954 was readily reversible either by washing the tissue or by reducing the stimulation frequency, whereas that produced by AH 5183 was difficult to reverse in these ways.3. Low doses of AH 5954 sensitized the rat hemidiaphragm preparation to the neuromuscular blocking action of choline. The neuromuscular block produced by choline was reversible by tetraethylammonium but not by neostigmine. This suggested that the blocking action of choline is at least partly pre-junctional in nature.4. In anaesthetized cats AH 5954 possessed a biphasic neuromuscular blocking action. The initial phase was rapid in onset, suggestive of a post-junctional action, whereas the second phase was prolonged and reversible by choline, suggestive of a prejunctional inhibitory action on the choline transport mechanism. AH 5183 produced no initial blocking action and was irreversible by choline.5. Both AH 5183 and AH 5954 possessed local anaesthetic and alpha-adrenoceptor blocking actions. These actions and the neuromuscular blocking action were affected to different degrees by quaternization, suggesting that the three main actions of the two drugs are independent.6. It was concluded that AH 5954 and AH 5183 act at different pre-junctional sites at the neuromuscular junction, AH 5954 acting extraneuronally by inhibiting choline transport and AH 5183 intraneuronally at the level of the synaptic vesicle membrane.
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000438:Alcohols / Q000494:pharmacology; D000772:Anesthesia, Local; D000818:Animals; D002415:Cats; D002645:Chickens; D002794:Choline / Q000037:antagonists & inhibitors / Q000494:pharmacology; D003510:Cyclohexanes / Q000494:pharmacology*; D004558:Electric Stimulation; D006967:Hypersensitivity; D066298:In Vitro Techniques; D009132:Muscles / Q000187:drug effects; D009388:Neostigmine / Q000494:pharmacology; D009467:Neuromuscular Depolarizing Agents / Q000494:pharmacology*; D009469:Neuromuscular Junction / Q000187:drug effects*; D010880:Piperidines / Q000494:pharmacology; D000644:Quaternary Ammonium Compounds / Q000494:pharmacology; D011817:Rabbits; D051381:Rats; D013757:Tetraethylammonium Compounds / Q000494:pharmacology
D000317:Adrenergic alpha-Antagonists; D000438:Alcohols; D003510:Cyclohexanes; D009467:Neuromuscular Depolarizing Agents; D010880:Piperidines; D000644:Quaternary Ammonium Compounds; D013757:Tetraethylammonium Compounds; D009388:Neostigmine; D002794:Choline